Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Concord Biotech Limited (CBL) is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation-based biopharmaceutical active pharmaceutical ingredients (APIs) sold worldwide.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #40 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 23 Sep 2024 | Prakash Lalchand Sajnani | Other | Sell | 0 | ₹0 |
| 23 Sep 2024 | Chandrashekhar Mukundrao Chawan | Other | Sell | 0 | ₹0 |
| 4 Sep 2024 | Devang Bhatt | Other | Sell | 0 | ₹0 |
| 13 Jun 2024 | Kanishka Kapoor | Immediate relative | Sell | 0 | ₹0 |
| 5 Jun 2024 | Ravi Kapoor | Director | Sell | 0 | ₹0 |
| 27 Feb 2024 | Rajendra Modi | Other | Sell | 0 | ₹0 |
| 27 Feb 2024 | Raksha Modi | Immediate relative | Sell | 0 | ₹0 |
| 24 Feb 2024 | Mr. Chandrashekhar Mukundrao Chawan | Other | Sell | 0 | ₹0 |
| 24 Feb 2024 | Raksha Modi | Immediate relative | Sell | 0 | ₹0 |
| 22 Nov 2023 | UTPAL SHETH | Other | Buy | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 31 Aug 2026 | DSP MUTUAL FUND | Bulk | Buy | 1,288,114 | 1404.1000 | BSE |
| 31 Aug 2026 | 1575773 ONTARIO INC | Bulk | Sell | 2,092,325 | 1404.1000 | BSE |
| 25 Feb 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Buy | 616,952 | 1217.9400 | NSE |
| 25 Feb 2026 | NK SECURITIES RESEARCH PRIVATE LIMITED | Bulk | Sell | 616,952 | 1218.5800 | NSE |
| 20 Sep 2024 | UBS PRINCIPAL CAPITAL ASIA LIMITED | Bulk | Sell | 740,159 | 2589.8600 | NSE |
| 20 Sep 2024 | THE VANGUARD GROUP INC A/C VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND | Bulk | Buy | 697,936 | 2596.0800 | NSE |
| 20 Sep 2024 | THE VANGUARD GROUP INC A/C VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANGUARD INTERNAT | Bulk | Buy | 577,183 | 2596.0800 | NSE |
| 28 May 2024 | NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL | Bulk | Buy | 600,000 | 1386.9500 | NSE |
| 28 May 2024 | 1575773 ONTARIO INC | Bulk | Sell | 3,548,211 | 1361.2600 | NSE |
| 25 Jan 2024 | SOCIETE GENERALE | Block | Buy | 153,421 | 1421.7000 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 24 Jul 2026 | Dividend - Rs 7.55 Per Share | 7.5500 | 24 Jul 2026 |
| 3 Sep 2025 | Dividend - Rs 10.70 Per Share | 10.7000 | 3 Sep 2025 |
| 21 Jun 2024 | Dividend - Rs 8.75 Per Share | 8.7500 | 22 Jun 2024 |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 21 Jun 2024 | OTHER | Annual General Meeting |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 23 Sep 2026 | Bonus | — |
| 31 Jul 2026 | Financial Results | Yes |
| 29 May 2026 | Financial Results/Dividend | Yes |
| 11 Feb 2026 | Financial Results | Yes |
| 13 Nov 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 28 Sep 2026 | Trading Window | Concord Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 28 Sep 2026 | Insider Trading / SAST | Concord Biotech Ltd - 543960 - Closure of Trading Window |
| 25 Sep 2026 | Copy of Newspaper Publication | Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication |
| 25 Sep 2026 | Company Update | Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Newspaper Publication |
| 24 Sep 2026 | Shareholders meeting | Concord Biotech Limited has informed the Exchange regarding Notice of Postal Ballot |
| 23 Sep 2026 | Bonus | Concord Biotech Limited has informed the Exchange that the Board of Directors at its meeting held on September 23, 2026, have considered and approved bonus at the ratio of 1 : 1, i.e 1 Equity Shares for every 1 Equity Shares held. |
| 19 Sep 2026 | Board Meeting | Concord Biotech Ltd - 543960 - Board Meeting Intimation for Meeting To Be Held On Wednesday, September 23, 2026, Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015 Inter-Alia To Consider The Proposal For Declaration Of Bonus Equity Shares To The Existing Equity Shareholders Of The Company |
| 18 Sep 2026 | Company Update | Concord Biotech Ltd - 543960 - Intimation Of Outcome Of U.S. Food And Drug Administration (USFDA) Inspection At Unit II - Valthera Formulation Facility Of The Company |
| 18 Sep 2026 | General Updates | Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II Valthera Formulation Facility of the Company |
| 17 Sep 2026 | Analysts/Institutional Investor Meet/Con. Call Updates | Concord Biotech Limited has informed the Exchange about Schedule of meet |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
